With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined and effective as possible.
Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to accurately predict clinical toxicity since they lack the fundamental complexity of in vivo tissue environments.
The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market (1,2). Many factors stand in the way of R&D productivity, not least of which are shrinking budgets. Yet one of the most pressing challenges continues to be the issue of ensuring that new drug candidates have an acceptable safety profile.
The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early as possible in the drug development process.
Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable functional heterogeneity in the human population.
Amyloid-related toxicity need not necessarily be the inevitable consequence of ageing, if some of the new drug discovery strategies to treat neurodegenerative and other ageing-related diseases succeed in the clinic.